PTC Therapeutics Paid $19.3 Million Over Face To Settle Its Last Old Convertible Notes

A July decision to settle in cash drove a debt loss, and the quarter also carried a $111.0 million expense for a Fabry gene therapy.

Share
PTC Therapeutics Paid $19.3 Million Over Face To Settle Its Last Old Convertible Notes

PTC Therapeutics, a biopharmaceutical company focused on rare disorders, booked a $19.3 million loss for settling the last $55.5 million of its 2026 convertible notes in cash, according to its 10-Q filed Thursday. The charge landed in the same quarter it expensed $111.0 million upfront for a Fabry disease gene therapy, and the company swung to a third-quarter net loss of $51.7 million.

Why cash settlement cost $19.3 million

On July 20, PTC sent the notes' trustee an irrevocable notice electing to settle the final conversions with a combination of cash and shares. That binding commitment to pay the excess value in cash disqualified the conversion feature from equity treatment, so PTC had to book it at fair value.

In September, $55.5 million of principal was converted, and the company paid $74.8 million in cash on September 15. The $19.3 million loss is the cash paid above principal, shown net of a $7.7 million gain on the change in the conversion option's fair value. PTC also paid $0.4 million of accrued interest.

The prior quarter's 10-Q carried no such charge. The notes had matured on September 15.

A $111.0 million Fabry purchase

PTC bought the ST-920 gene therapy for Fabry disease from Sangamo Therapeutics under an August 25 agreement that closed September 17. It paid $111.0 million in cash, booked as acquired in-process research and development, and may owe up to $100.0 million more if regulatory milestones are met. Those milestone payments will be capitalized when they become payable.

PTC expects to finish a rolling submission to the FDA for accelerated approval in the fourth quarter of 2026.

In the quarter, net product revenue was $275.9 million, against $131.0 million a year earlier, and Sephience sales were $181.9 million. Total revenue reached $357.8 million. The loss compares with net income of $15.9 million a year earlier; for nine months, net income was $29.0 million against $817.6 million.

The refinancing and the milestone bill

In June, PTC issued $550.0 million of zero-coupon convertible notes due 2031 and used about $328.8 million of the proceeds to repurchase $222.0 million of the old notes. That left the $55.5 million stub settled in September.

A milestone payable to former Censa securityholders stood at $80.0 million on the balance sheet at September 30, up from $416 thousand at December 31, after Sephience sales crossed the contractual thresholds. Cash and marketable securities were $2.13 billion.

The company's $80.0 million Censa milestone is a payable now, while the $100.0 million owed to Sangamo comes due only if ST-920 wins regulatory approvals.

Sources

More on PTC Therapeutics

All PTC Therapeutics (PTCT) coverage →